NCT05967429

Predictors of Sorafenib Response in HCC

Predictors of Sorafenib Response in Patients With Advanced Hepatocellular Carcinoma

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 80 (estimated)
• Sponsor: Sohag University · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: —

Summary

Evaluating the nutrition status of patients with advanced HCC who received sorafenib. Using the pretreatment nutrition status and quality of life as predictors to sorafenib response

Detailed description

This a cross sectional study will be conducted on 100 HCC treated with sorafenib Data were gathered from medical records, including age sex body weight and height (BMI) pre-therapy laboratory counts of white cells, neutrophils, lymphocytes, monocyte, hemoglobin and platelets; bilirubin, albumin and globulin concentration, AST, ALT, AFP, PT and CONC Barcelona Clinic Liver Cancer Stage (BCLC) of all patients The neutrophil-to- lymphocyte ratio (NLR) was calculated by dividing the neutrophil count by the lymphocyte count. The platelet- to-lymphocyte ratio (PLR) was calculated by dividing the platelet count by the lymphocyte count. Weight loss difference after treatment Portal hypertension was defined as presence of either collaterals on radiological examination, esophageal varices by upper gastrointestinal endoscopy and/or thrombocytopenia. Quality of life assessment. QoL was assessed using FACT Hepatobiliary Symptom Index (FHSI-8) Questionnaire. QoL was assessed at base line and 3-6 months after start of treatment.

Conditions

• Hepatocellular Carcinoma

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	The neutrophil-to- lymphocyte ratio	It was calculated by dividing the neutrophil count by the lymphocyte count.
DIAGNOSTIC_TEST	Prognostic nutrition index	It was calculated using the following formula: serum albumin (g/L) + 0.005 × total lymphocyte count/μL

Timeline

• Start date: 2023-08-01
• Primary completion: 2024-04-01
• Completion: 2024-06-01
• First posted: 2023-08-01
• Last updated: 2023-08-01